Literature DB >> 14761205

Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.

Luo Yan1, Christa E Müller.   

Abstract

Many currently known antagonists for P2 purinergic receptors are anionic molecules bearing one or several phenylsulfonate groups. Among the P1 (adenosine) receptor antagonists, the xanthine phenylsulfonates are a potent class of compounds. Due to their high acidity, phenylsulfonates are negatively charged at physiologic pH values and do not easily penetrate cell membranes. The present study was aimed at developing lipophilic, perorally bioavailable prodrugs of sulfonates by converting them into chemically stable nitrophenyl esters. Initial stability tests at different pH values using nitrophenyl tosylates as model compounds showed that m-nitrophenyl esters were stable over a wide pH range, while the ortho and para isomers were less stable under strongly acidic or basic conditions. A series of m- and p-nitrophenyl esters of p-sulfophenylxanthine derivatives were synthesized as model compounds. The target xanthine derivatives were obtained in high yields by condensation of the appropriate 5,6-diaminouracils with 4-(nitrophenoxysulfonyl)benzoic acids in the presence of a carbodiimide, followed by ring closure with polyphosphoric acid trimethylsilyl ester. The chemical and enzymatic stability of the m-nitrophenyl esters was investigated in vitro by means of capillary electrophoresis. High stability in aqueous solution, in artificial gastric acid, and in serum was observed. However, compound 5d, used as a prototypic xanthine m-nitrophenylsulfonate, was hydrolyzed by rat liver homogenate indicating an enzymatic pathway of hydrolysis. Thus, nitrophenyl esters of sulfonic acids have a potential as peroral prodrugs of drugs bearing a sulfonate group. The nitrophenyl esters of sulfophenylxanthines were additionally investigated for their adenosine receptor affinities. They showed high affinity at A(1), A(2A), and A(2B), but not at A(3) ARs. One of the most potent compounds was 1-propyl-8-[4-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine (9d), a mixed A(1)/A(2B) antagonist (K(i)A(1) 3.6 nM, K(i)A(2B) 5.4 nM) selective versus the other subtypes. As a further result of this study, the m-nitrophenoxy group was found to be a suitable protecting group for sulfonates in organic synthesis due to its high lipophilicity and stability; it can be split off under strongly basic conditions. This new protection strategy allowed for the upscaling of the synthesis of 1-propyl-8-p-sulfophenylxanthine (PSB-1115), a selective A(2B) antagonist.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14761205     DOI: 10.1021/jm0310030

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Authors:  Sebastian Michael; Heba Abdel-Aziz; Dieter Weiser; Christa E Müller; Olaf Kelber; Karen Nieber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-10       Impact factor: 3.000

Review 2.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

3.  Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

Authors:  Almut Grenz; Jessica D Bauerle; Julee H Dalton; Douglas Ridyard; Alexander Badulak; Eunyoung Tak; Eóin N McNamee; Eric Clambey; Radu Moldovan; German Reyes; Jost Klawitter; Kelly Ambler; Kristann Magee; Uwe Christians; Kelley S Brodsky; Katya Ravid; Doo-Sup Choi; Jiaming Wen; Dmitriy Lukashev; Michael R Blackburn; Hartmut Osswald; Imogen R Coe; Bernd Nürnberg; Volker H Haase; Yang Xia; Michail Sitkovsky; Holger K Eltzschig
Journal:  J Clin Invest       Date:  2012-01-24       Impact factor: 14.808

4.  Adenosine A(2A) agonist and A(2B) antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation.

Authors:  Sebastian Michael; Claudia Warstat; Fabien Michel; Luo Yan; Christa E Müller; Karen Nieber
Journal:  Purinergic Signal       Date:  2009-12-18       Impact factor: 3.765

5.  Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists.

Authors:  Ali El-Tayeb; Sebastian Michael; Aliaa Abdelrahman; Andrea Behrenswerth; Sabrina Gollos; Karen Nieber; Christa E Müller
Journal:  ACS Med Chem Lett       Date:  2011-10-10       Impact factor: 4.345

6.  Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats.

Authors:  Marcello Solinas; Sergi Ferré; Katerina Antoniou; Davide Quarta; Zuzana Justinova; Jörg Hockemeyer; Lara A Pappas; Pavan N Segal; Carrie Wertheim; Christa E Müller; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-02-05       Impact factor: 4.530

7.  Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine.

Authors:  Jiang-Ning Yang; Jiang-Fan Chen; Bertil B Fredholm
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-13       Impact factor: 4.733

8.  Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis.

Authors:  Julia-Stefanie Frick; Christopher F MacManus; Melanie Scully; Louise E Glover; Holger K Eltzschig; Sean P Colgan
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

9.  Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.

Authors:  Andreas Brunschweiger; Jamshed Iqbal; Frank Umbach; Anja B Scheiff; Mercedes N Munkonda; Jean Sévigny; Aileen F Knowles; Christa E Müller
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

10.  Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia.

Authors:  Andras Bilkei-Gorzo; Osama M Abo-Salem; Alaa M Hayallah; Kerstin Michel; Christa E Müller; Andreas Zimmer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.